Antibody Response Following Pre-Exposure Immunization Against Rabies in High-Risk Professionals.
Vector Borne Zoonotic Dis
; 20(4): 303-309, 2020 04.
Article
in En
| MEDLINE
| ID: mdl-31794689
ABSTRACT
Vaccination against rabies and routine antibody testing of subjects participating in programs for the surveillance and control of rabies in animals is strongly recommended. The scope of this study is to describe the antibody level as measured by a commercial enzyme-linked immunosorbent assay (ELISA) after primary and booster intramuscular vaccination with a purified vero-cell rabies vaccine (PVRV) in high-risk professionals and to determine the influence of an array of factors on antibody level, that is, time elapsed since primary immunization series and booster dose, sex, age, pathologic conditions, high-risk occupation, and peak antibody level after initial scheme and booster dose. A primary series of three doses of PVRV was administered and a commercial ELISA was recommended 14 days postimmunization with continuous repetition at 6 months and yearly intervals for the laboratory personnel and the rest of the professionals, respectively. The protective antibody titer was defined as a minimum of 0.5 equivalent units/mL (EU/mL) (seroconvertion) and a booster dose was applied if the titer was determined nonprotective. The seroconversion rate (SCR) after primary vaccination was 100%, with a geometric mean titer (GMT) of 2.90 EU/mL (interquartile range [IQR] 1.85-3.45). After booster vaccination due to nonprotective titer, the SCR was 100% and the GMT increased by 678% (95% confidence interval [CI] 514-887) reaching 4.25 EU/mL (IQR 4.00-4.60), 2.5 times higher than the GMT elicited by the primary vaccine scheme in the respective recipients. The titer dropped by 1.20% per month (95% CI 0.52-1.89) regardless of booster administration or any other factor. Women had 51% higher titer compared with men (95% CI 6-116). High-risk professionals should be verified for adequate antibody titers, but routine administration of a single booster dose of PVRV 1 year after the primary series could be considered; more evidence is needed to support the benefit in terms of immunity and logistics.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Rabies
/
Rabies virus
/
Rabies Vaccines
/
Occupational Exposure
/
Antibodies, Viral
Type of study:
Etiology_studies
/
Risk_factors_studies
/
Screening_studies
Limits:
Animals
/
Humans
Language:
En
Journal:
Vector Borne Zoonotic Dis
Journal subject:
DOENCAS TRANSMISSIVEIS
/
EPIDEMIOLOGIA
Year:
2020
Document type:
Article
Affiliation country:
Greece